Financial - Conglomerates
Compare Stocks
4 / 10Stock Comparison
TDACW vs HCAI vs IIPR vs BRTX
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
REIT - Industrial
Biotechnology
TDACW vs HCAI vs IIPR vs BRTX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Financial - Conglomerates | Industrial - Machinery | REIT - Industrial | Biotechnology |
| Market Cap | $466K | $16M | $1.62B | $2M |
| Revenue (TTM) | $0.00 | $41M | $263M | $383K |
| Net Income (TTM) | $5M | $1M | $120M | $-13M |
| Gross Margin | — | 14.0% | 60.3% | 79.6% |
| Operating Margin | — | 5.5% | 46.7% | -37.9% |
| Forward P/E | — | 9.7x | 13.2x | — |
| Total Debt | $0.00 | $12M | $394M | $0.00 |
| Cash & Equiv. | $438K | $29K | $48M | $548K |
TDACW vs HCAI vs IIPR vs BRTX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 25 | May 26 | Return |
|---|---|---|---|
| Translational Devel… (TDACW) | 100 | 32.6 | -67.4% |
| Hauchen AI Parking … (HCAI) | 100 | 10.5 | -89.5% |
| Innovative Industri… (IIPR) | 100 | 78.7 | -21.3% |
| BioRestorative Ther… (BRTX) | 100 | 14.8 | -85.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TDACW vs HCAI vs IIPR vs BRTX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TDACW lags the leaders in this set but could rank higher in a more targeted comparison.
HCAI is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.63
- Lower volatility, beta 0.63, Low D/E 41.5%, current ratio 2.58x
- Beta 0.63, current ratio 2.58x
- Better valuation composite
IIPR carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 436.4% 10Y total return vs TDACW's -70.6%
- 45.6% margin vs BRTX's -33.0%
- 13.5% yield; 9-year raise streak; the other 3 pay no meaningful dividend
- +20.3% vs HCAI's -94.0%
BRTX is the clearest fit if your priority is growth exposure.
- Rev growth 175.0%, EPS growth 53.0%, 3Y rev CAGR 105.8%
- 175.0% revenue growth vs IIPR's -13.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 175.0% revenue growth vs IIPR's -13.8% | |
| Value | Better valuation composite | |
| Quality / Margins | 45.6% margin vs BRTX's -33.0% | |
| Stability / Safety | Beta 0.63 vs BRTX's 2.21 | |
| Dividends | 13.5% yield; 9-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +20.3% vs HCAI's -94.0% | |
| Efficiency (ROA) | 5.1% ROA vs BRTX's -224.5%, ROIC 4.3% vs -100.4% |
TDACW vs HCAI vs IIPR vs BRTX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
TDACW vs HCAI vs IIPR vs BRTX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IIPR leads in 3 of 6 categories
HCAI leads 1 • TDACW leads 0 • BRTX leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IIPR leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IIPR and TDACW operate at a comparable scale, with $263M and $0 in trailing revenue. IIPR is the more profitable business, keeping 45.6% of every revenue dollar as net income compared to BRTX's -33.0%. On growth, IIPR holds the edge at -3.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $41M | $263M | $383,400 |
| EBITDAEarnings before interest/tax | -$915,583 | — | $197M | -$14M |
| Net IncomeAfter-tax profit | $5M | — | $120M | -$13M |
| Free Cash FlowCash after capex | -$2M | — | $144M | -$11M |
| Gross MarginGross profit ÷ Revenue | — | +14.0% | +60.3% | +79.6% |
| Operating MarginEBIT ÷ Revenue | — | +5.5% | +46.7% | -37.9% |
| Net MarginNet income ÷ Revenue | — | +3.7% | +45.6% | -33.0% |
| FCF MarginFCF ÷ Revenue | — | +3.7% | +54.7% | -28.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -72.8% | -3.8% | -94.9% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -62.7% | -1.0% | -153.8% |
Valuation Metrics
HCAI leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
At 9.7x trailing earnings, HCAI trades at a 33% valuation discount to IIPR's 14.4x P/E. On an enterprise value basis, HCAI's 8.8x EV/EBITDA is more attractive than IIPR's 9.9x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $465,750 | $16M | $1.6B | $2M |
| Enterprise ValueMkt cap + debt − cash | $27,576 | $27M | $2.0B | $1M |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | 9.71x | 14.40x | -0.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 13.17x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 3.85x | — |
| EV / EBITDAEnterprise value multiple | — | 8.84x | 9.91x | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.38x | 6.08x | 4.48x |
| Price / BookPrice ÷ Book value/share | 0.01x | 0.52x | 0.87x | 0.20x |
| Price / FCFMarket cap ÷ FCF | — | 10.43x | 9.26x | — |
Profitability & Efficiency
IIPR leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
IIPR delivers a 6.4% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-6 for BRTX. IIPR carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCAI's 0.42x. On the Piotroski fundamental quality scale (0–9), HCAI scores 7/9 vs BRTX's 2/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -0.1% | +5.5% | +6.4% | -5.7% |
| ROA (TTM)Return on assets | +2.6% | +3.0% | +5.1% | -2.2% |
| ROICReturn on invested capital | -0.2% | +4.2% | +4.3% | -100.4% |
| ROCEReturn on capital employed | -0.2% | +7.0% | +5.8% | -124.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 0.42x | 0.21x | — |
| Net DebtTotal debt minus cash | -$438,174 | $12M | $346M | -$547,890 |
| Cash & Equiv.Liquid assets | $438,174 | $28,654 | $48M | $547,890 |
| Total DebtShort + long-term debt | $0 | $12M | $394M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | 4.00x | 6.67x | — |
Total Returns (Dividends Reinvested)
IIPR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IIPR five years ago would be worth $4,999 today (with dividends reinvested), compared to $64 for BRTX. Over the past 12 months, IIPR leads with a +20.3% total return vs HCAI's -94.0%. The 3-year compound annual growth rate (CAGR) favors IIPR at 4.5% vs BRTX's -64.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -66.4% | +61.6% | +18.3% | -81.6% |
| 1-Year ReturnPast 12 months | -64.3% | -94.0% | +20.3% | -87.5% |
| 3-Year ReturnCumulative with dividends | -64.3% | -87.4% | +14.1% | -95.7% |
| 5-Year ReturnCumulative with dividends | -95.8% | -87.4% | -50.0% | -99.4% |
| 10-Year ReturnCumulative with dividends | -70.6% | -87.4% | +436.4% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -29.1% | -49.9% | +4.5% | -64.9% |
Risk & Volatility
Evenly matched — TDACW and IIPR each lead in 1 of 2 comparable metrics.
Risk & Volatility
TDACW is the less volatile stock with a -0.76 beta — it tends to amplify market swings less than BRTX's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IIPR currently trades 92.2% from its 52-week high vs HCAI's 4.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.76x | 0.63x | 0.92x | 2.21x |
| 52-Week HighHighest price in past year | $0.42 | $318.60 | $61.40 | $2.05 |
| 52-Week LowLowest price in past year | $0.06 | $0.32 | $44.58 | $0.19 |
| % of 52W HighCurrent price vs 52-week peak | +23.9% | +4.6% | +92.2% | +11.0% |
| RSI (14)Momentum oscillator 0–100 | 37.5 | 65.3 | 59.3 | 46.8 |
| Avg Volume (50D)Average daily shares traded | 9K | 1.5M | 303K | 5.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
IIPR is the only dividend payer here at 13.46% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Hold | — |
| Price TargetConsensus 12-month target | — | — | $44.00 | — |
| # AnalystsCovering analysts | — | — | 11 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | +13.5% | — |
| Dividend StreakConsecutive years of raises | — | — | 9 | — |
| Dividend / ShareAnnual DPS | — | — | $7.62 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.2% | 0.0% |
IIPR leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCAI leads in 1 (Valuation Metrics). 1 tied.
TDACW vs HCAI vs IIPR vs BRTX: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is TDACW or HCAI or IIPR or BRTX a better buy right now?
For growth investors, BioRestorative Therapies, Inc.
(BRTX) is the stronger pick with 175. 0% revenue growth year-over-year, versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). Hauchen AI Parking Management Technology Holding Co. , Ltd. (HCAI) offers the better valuation at 9. 7x trailing P/E, making it the more compelling value choice. Analysts rate Innovative Industrial Properties, Inc. (IIPR) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TDACW or HCAI or IIPR or BRTX?
On trailing P/E, Hauchen AI Parking Management Technology Holding Co.
, Ltd. (HCAI) is the cheapest at 9. 7x versus Innovative Industrial Properties, Inc. at 14. 4x.
03Which is the better long-term investment — TDACW or HCAI or IIPR or BRTX?
Over the past 5 years, Innovative Industrial Properties, Inc.
(IIPR) delivered a total return of -50. 0%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: IIPR returned +436. 4% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TDACW or HCAI or IIPR or BRTX?
By beta (market sensitivity over 5 years), Translational Development Acquisition Corp.
(TDACW) is the lower-risk stock at -0. 76β versus BioRestorative Therapies, Inc. 's 2. 21β — meaning BRTX is approximately -391% more volatile than TDACW relative to the S&P 500. On balance sheet safety, Innovative Industrial Properties, Inc. (IIPR) carries a lower debt/equity ratio of 21% versus 42% for Hauchen AI Parking Management Technology Holding Co. , Ltd. — giving it more financial flexibility in a downturn.
05Which is growing faster — TDACW or HCAI or IIPR or BRTX?
By revenue growth (latest reported year), BioRestorative Therapies, Inc.
(BRTX) is pulling ahead at 175. 0% versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). On earnings-per-share growth, the picture is similar: BioRestorative Therapies, Inc. grew EPS 53. 0% year-over-year, compared to -54. 2% for Translational Development Acquisition Corp.. Over a 3-year CAGR, BRTX leads at 105. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TDACW or HCAI or IIPR or BRTX?
Innovative Industrial Properties, Inc.
(IIPR) is the more profitable company, earning 43. 0% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps 43. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIPR leads at 46. 7% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — BRTX leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — TDACW or HCAI or IIPR or BRTX?
In this comparison, IIPR (13.
5% yield) pays a dividend. TDACW, HCAI, BRTX do not pay a meaningful dividend and should not be held primarily for income.
08Is TDACW or HCAI or IIPR or BRTX better for a retirement portfolio?
For long-horizon retirement investors, Translational Development Acquisition Corp.
(TDACW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 76)). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TDACW: -70. 6%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TDACW and HCAI and IIPR and BRTX?
These companies operate in different sectors (TDACW (Financial Services) and HCAI (Industrials) and IIPR (Real Estate) and BRTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TDACW is a small-cap quality compounder stock; HCAI is a small-cap high-growth stock; IIPR is a small-cap deep-value stock; BRTX is a small-cap high-growth stock. IIPR pays a dividend while TDACW, HCAI, BRTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.